Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PN-232 · 1 trial · 1 indication
Number and Severity of Adverse Events
| Arm | Type | Description |
|---|---|---|
| Single Dose | EXPERIMENTAL | Single dose administration |
| Multiple Dose | EXPERIMENTAL | Multiple dose administration |
| Solid Dose Comparison | EXPERIMENTAL | Solid dose administration |
| Name | Type | Description |
|---|---|---|
| PN-232 | DRUG | Active Drug |
| Placebo | DRUG | Matching Placebo |
Key Inclusion Criteria: * Subjects must have BMI between 18 and 32 kg/m2 * Subjects must be non-smokers or social smokers * Subjects must comply with contraception requirements * Subjects must be willing to consume meals provided by the clinical center * Subjects must be willing to attend required ...
PN-232 is an investigational small molecule developed by Protagonist Therapeutics, Inc. (NASDAQ: PTGX). It is designed to target the IL-23 receptor and has been studied in a Phase 1 clinical trial in healthy volunteers. The specific therapeutic indications for PN-232 have not been disclosed.
PN-232 targets the IL-23 receptor. By binding to this receptor, it is intended to modulate IL-23 signaling, a pathway involved in inflammatory responses. The drug is a small molecule and is being developed by Protagonist Therapeutics.
PN-232 is being developed by Protagonist Therapeutics, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol PTGX. The company is responsible for the clinical development of PN-232.
PN-232 is in Phase 1 clinical development. A Phase 1 trial has been completed, and no active trials are currently listed. The drug remains investigational and has not been approved by the FDA.
PN-232 has been evaluated in a Phase 1 clinical trial, NCT04819620, titled "Pharmacokinetics of PN-232 in Healthy Volunteers." This completed trial enrolled 48 healthy adult participants in Australia and used a randomized, double-blind, controlled design.